Fig. 3From: FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancerClinical course of serum carcinoembryonic antigen (CEA) levels during treatment. Serum CEA level decreased from 1335.0 to 108.4Â ng/mL after six courses of nivolumab treatmentBack to article page